Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy.

In contrast to the plateau detected for miR-218 levels at 12.5 and 40 mg/kg, Mbnl1 transcripts and protein amount increased steadily with dose in both muscles, although the statistical differences were more or less significant depending on the magnitude of the error.

also in 311 other papers